Disitamab Vedotin, Tislelizumab, and S-1 Deliver High Response Rates in HER2-Overexpressing Advanced Gastric/GEJ Cancer
HER2-targeted therapy has improved outcomes in advanced gastric and gastroesophageal junction adenocarcinoma, but resistance and heterogeneous HER2 expression continue to limit long-term disease…
Read the full articleYou might also wanna read
Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study
Conditions : Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; HER2-positive Gastric Cancer Interventions : Drug: Zanidatamab; Drug:
Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial
Savolitinib shows promise for MET^amp^ gastric/GEJ cancer: Phase 2 data reveal potential as a targeted therapy in this poor prognosis group.
Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II
Conditions : Esophageal Squamous Cell Carcinoma Interventions : Drug: Becotatug Vedotin; Drug: Tislelizumab; Drug: Lenvatinib Sponsors : Tia
Sac-TMT Combined With Fruquintinib as Second-Line Treatment in Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Conditions : Gastric Adenocarcinoma; Gastroesophageal Junction (GEJ) Adenocarcinoma; Gastro-esophageal Junction Adenocarcinoma Interventions
Becotatugvedotin Plus Pucotenlimab in EGFR-Positive Advanced Gastric/GEJ Adenocarcinoma
Conditions : Gastric Cancer; Gastroesophageal Junction (GEJ) Adenocarcinoma; Becotatug Vedotin; Pucotenlimab Interventions : Drug: Becotatug
Personalized Treatment Strategies for HER2-Positive Gastroesophageal Adenocarcinoma
Stay current with evolving strategies for HER2-positive gastroesophageal adenocarcinoman (GEA). Improve your practice with continuing educat
mdsc.pe·21d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.